|Day Low/High||614.11 / 633.84|
|52 Wk Low/High||271.37 / 655.93|
With Pfizer deal dead, Allergan is ready to go shopping.
The biopharmaceutical company's chart is still pointed lower.
TheStreet’s Jim Cramer discussed the bear market in biotechs while answering viewer questions from social media on Friday.
U.S. stocks gave up earlier gains as the energy sector continued to sell off despite relatively stable crude prices on Tuesday.
The biopharmaceutical company is in for a deeper bear phase.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.
5 biotech stocks that could outperform the overall market in 2016.
TheStreet looked at stocks that soared under the Federal Reserve’s QE program, and Jim Cramer explains why some shares performed better than others.
TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.
Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...
The common thread in these 5 names is the bullish divergence between the lower lows in price and the higher low in the momentum study.
The company's stock will likely be among the first to turn.
Before you sell them, ask yourself at what multiple you sell.
Jim Cramer answered viewers’ Twitter (TWTR) questions from the floor of the Stock Exchange and said he's not assuaged by Glencore's (GLCNF) comments that it is ‘operationally and financially robust.'
High-growth, REIT and consumer names clearly want to go higher.